CLCS (Cell Source) EPS without NRI: $-0.14 (TTM As of Dec. 2024)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.82
View Full Analysis

What is Cell Source EPS without NRI?

Cell Source CLCS +9.33% 35 EPS without NRI is $-0.14 as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Cell Source's earnings per share without non-recurring items for the three months ended in Dec. 2024 was $-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cell Source's EPS without NRI or its related term are showing as below:

CLCS's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Cell Source's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.13.

Cell Source's EPS (Basic) for the three months ended in Dec. 2024 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.13.


Cell Source  (OTCPK:CLCS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cell Source EPS without NRI Related Terms


Cell Source EPS without NRI Historical Data

* Premium members only.

The historical data trend for Cell Source's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source EPS without NRI Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.19 -0.19 -0.18 -0.17 -0.15

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.04 -0.04 -0.04 -0.02

CLCS vs EDSA, CTXR, ASBP: EPS without NRI Comparison

For the Biotechnology subindustry, Cell Source's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cell Source's PE Ratio without NRI falls into.


CLCS
35GF Score
Cell Source Inc CLCS
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.14 mean?
Cell Source (CLCS) has a EPS without NRI of $-0.14 as of Dec. 2024. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cell Source and its competitors.
Is Cell Source's EPS without NRI too high?
Cell Source's current EPS without NRI is $-0.14. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's EPS without NRI compare to EDSA and CTXR?
Cell Source's EPS without NRI of $-0.14 can be compared against companies in the Biotechnology industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cell Source and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current EPS without NRI is $-0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current EPS without NRI of $-0.14. The current EPS without NRI is $-0.14. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Cell Source (CLCS), the current EPS without NRI is $-0.14 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.82
Price